Circulating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that
originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as …

Circulating tumor DNA (ctDNA) in fluids has gained attention because ctDNA seems to
identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of …

Simple Summary Mouth cancer often results in poor outcomes and requires the use of state-
of-the-art medical approaches to make its detection easy, individualized, and early. Liquid …

Ovarian cancer (OC) is the most lethal cancer of all gynecological malignancies, while
endometrial cancer (EC) is the most common one. Current strategies for OC/EC diagnosis …

The conventional method used to obtain a tumor biopsy for hepatocellular carcinoma (HCC)
is invasive and does not evaluate dynamic cancer progression or assess tumor …

Recent advances in molecular technologies enable sensitive and quantitative assessment
of circulating tumor DNA, offering a noninvasive disease monitoring tool for patients with …

Minimal residual disease (MRD) refers to a very small number of residual tumor cells in the
body during or after treatment, representing the persistence of the tumor and the possibility …

Although prostate cancer (PCa) is one of the most common tumors in European males, the
only minimally invasive diagnostic tool in PCa setup is the determination of PSA in serum …

Simple Summary Monitoring the response to treatment in hematologic malignancies is
essential in defining the best way to optimize patient management. In general, achieving a …

Circulating tumor DNA (ctDNA), as a next-generation tumor marker, enables early screening
and monitoring of cancer through noninvasive testing. Exploring the development of new …